Baker J H, Goodpasture H C, Kuhns H R, Rinaldi M G
Department of Internal Medicine, University of Kansas School of Medicine, Wichita.
Arch Pathol Lab Med. 1989 Nov;113(11):1279-81.
A 58-year-old, alcoholic, diabetic man presented with multiple, ulcerated skin lesions and polymicrobial septicemia. Sporothrix schenckii was recovered from blood cultures and was resistant to amphotericin B by in vitro testing. Amphotericin B therapy failed, but the patient responded dramatically to itraconazole therapy, only to relapse 3 months after therapy was stopped. Reinstitution of itraconazole therapy has produced another dramatic response. This report is noteworthy for three reasons. First, to our knowledge, it represents only the second reported instance of fungemia with S schenckii that responded to medical therapy. Second, it illustrates that in vitro antifungal susceptibility tests may predict clinical infection response to drug therapy. Third, it suggests that itraconazole has significant promise in treating systemic sporotrichosis.
一名58岁的酗酒糖尿病男性,出现多处溃疡性皮肤病变及多种微生物败血症。从血培养中分离出申克孢子丝菌,体外试验显示其对两性霉素B耐药。两性霉素B治疗失败,但患者对伊曲康唑治疗反应显著,然而在治疗停止3个月后复发。重新使用伊曲康唑治疗又产生了显著疗效。本报告因三个原因值得关注。首先,据我们所知,这是第二例报告的申克孢子丝菌血症经药物治疗有效的病例。其次,它表明体外抗真菌药敏试验可预测临床感染对药物治疗的反应。第三,它提示伊曲康唑在治疗系统性孢子丝菌病方面有很大前景。